.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

The Evolving Landscape of Immunotherapy for NSCLC

EP. 1: The Ever-Evolving Treatment Paradigm for NSCLC

July 13th 2017

EP. 2: Upfront Immunotherapy for NSCLC

July 13th 2017

EP. 3: Upfront Immunotherapy + Chemotherapy for NSCLC

July 13th 2017

EP. 4: Early Experience; Immunotherapy + Chemotherapy for NSCLC

July 13th 2017

EP. 5: Immunotherapy for Relapsed/Refractory NSCLC

July 13th 2017

EP. 6: Questions Surrounding Therapeutic Sequencing for NSCLC

July 13th 2017

EP. 7: Unmet Needs: Sequencing After Immunotherapy in NSCLC

July 13th 2017

EP. 8: Emerging Immunotherapies and Combinations for NSCLC

July 13th 2017

EP. 9: Novel Immunotherapy Combinations for NSCLC

July 13th 2017

EP. 10: Immunotherapy for Operable NSCLC

July 13th 2017